In Q4 2025, Merck & Co., Inc. reported a quarterly revenue of $12.3 billion and a net income of $5.6 billion. This represents significant growth from the previous quarter, with revenue increasing by 9.3% and profit growth of 18.05%. Year-over-year, Merck's revenue grew by 3.72%, while its net income increased by an impressive 64.51%.
Merck's strong Q4 earnings were driven in part by the continued growth of Keytruda, its blockbuster cancer drug. In addition, the Animal Health segment also showed robust growth during this period. These positive catalysts helped offset weaker-than-expected 2026 guidance, maintaining a positive outlook for the company.
Despite these strengths, there are potential concerns to consider. Merck's 2026 guidance fell short of expectations, which may impact investor confidence. However, it's important to note that this is just one quarter's worth of data and should not be viewed in isolation.
Looking at the company's performance over time, Merck has maintained steady growth across both revenue and profitability metrics. With a 3-year revenue CAGR of None% and a 3-year profit CAGR of None%, Merck has consistently outperformed its sector averages. Additionally, its operating margin stands at an impressive 34.86%, which is significantly higher than the sector average of 14.5%.
Moving forward, investors should keep a close eye on Merck's continued growth in Keytruda and the Animal Health segment. While there are potential concerns about guidance, it's important to remember that this is just one quarter's worth of data and should not be viewed as a significant red flag. With its strong financial performance and positive outlook for the future, Merck & Co., Inc. remains a compelling investment opportunity for those looking for growth in the healthcare sector.